Skip to main content

Erdanib 4 mg & 5 mg (Erdafitinib)

The specific manufacturer of Erdanib is currently: Drug International Limited

This distinction is important because the documented development history of erdafitinib does not establish the manufacturer of every product sold under another brand name.

Erdafitinib development

Astex Pharmaceuticals states that erdafitinib was discovered through its FGFR inhibitor program in collaboration with Janssen. The collaboration began in 2008, with Janssen responsible for clinical development and commercialization of products arising from the collaboration.

Reference product

BALVERSA is the established branded erdafitinib product in the principal regulatory sources reviewed for this website. Current U.S. labeling identifies Janssen Products LP as the packager in DailyMed.

Different pharmaceutical roles

These terms should not be treated as interchangeable:

  • Discoverer/developer: organization involved in discovering or developing the medicine.
  • Originator: the developer associated with the original medicinal product.
  • Manufacturer: entity manufacturing a particular medicinal product.
  • Brand owner: entity controlling a commercial brand.
  • Marketing authorization holder: entity legally responsible for an authorization in a particular jurisdiction.
  • Distributor: entity responsible for distribution.
  • Supplier: party supplying the product through a commercial channel.

Astex Pharmaceuticals

Astex was founded in Cambridge, UK, and developed a fragment-based drug-discovery platform. Its published history identifies partnerships with pharmaceutical companies and describes its later acquisition by Otsuka.

Janssen

Janssen entered an exclusive worldwide license and collaboration agreement with Astex in 2008 to develop and commercialize erdafitinib.

Erdanib relationship

The relationship between Erdanib and these organizations is not established by the available product documentation.